Clinical Trials Logo

Atrial Fibrillation New Onset clinical trials

View clinical trials related to Atrial Fibrillation New Onset.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05841056 Not yet recruiting - Clinical trials for Atrial Fibrillation New Onset

Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial

START-POAF
Start date: May 31, 2024
Phase: Phase 3
Study type: Interventional

The START-POAF pilot study is a prospective, open-label two-arm, randomized controlled trial with blinded assessment of outcomes (PROBE). This pilot study will assess Atrial Fibrillation (AF) recurrence and burden in patients with new-onset AF following cardiac surgery.

NCT ID: NCT03991754 Not yet recruiting - Clinical trials for Atrial Fibrillation New Onset

Prevention of New Onset AF After TAVI (PAF-TAVI Trial)

PAF-TAVI
Start date: June 30, 2019
Phase: Phase 3
Study type: Interventional

New onset atrial fibrillation (NOAF) is a relatively frequent complication after transcatheter aortic valve implantation (TAVI). This complication has been related with worse short and long-term outcomes, including higher stroke, mortality, readmission and bleeding rates. The aim of this study is to evaluate the effectiveness of amiodarone in the prevention of the NOAF after TAVI. The study is a multicenter, randomized double-blinded trial including 120 patients without prior AF that will undergo TAVI in a scheduled basis. Patients will be randomized to be treated with amiodarone orally from 6 days before to 6 days after the TAVI procedure versus placebo. All the patients will be monitored with a 60-day holter to evaluate NOAF incidence. The main objective is NOAF incidence after TAVI at 30-day. Secondary endpoints are the incidence of NOAF, stroke, bleeding and all-cause and cardiovascular mortality in both groups at 60-day. Results of this study can contribute to optimize TAVI results in a short and long term, potentially improving the survival and quality of life in this group of frail patients with comorbidities, which makes them vulnerable to NOAF, stroke, bleeding, heart failure and readmission.

NCT ID: NCT03382990 Not yet recruiting - Clinical trials for Acute Myocardial Infarction

Stent Placement and the Risk of New-onset AF in Patients With AMI

Start date: January 1, 2018
Phase: N/A
Study type: Observational

The benefit of a drug-eluting stent (DES) in patients with acute myocardial infarction (AMI) is controversial. This study will aim to observe the effect of a DES on the risk of new-onset AF in patients with AMI.